The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes of patients with treated secondary AML: a large retrospective analysis
Jayastu Senapati, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study exploring the outcomes of patients with treated secondary acute myeloid leukemia (sAML), a high-risk subtype of AML arising from previously treated myeloid neoplasms. Dr Senapati notes that irrespective of genomics, patients with treated sAML have inferior outcomes, with median survival ranging from nine to 12 months. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
